{"organizations": [], "uuid": "41afb881b0eccec101af2c71f51a8ffdb806e27a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/us-merck-results-partnerships/germanys-merck-seeks-drug-development-partners-idUSKCN1GK1H0", "country": "US", "domain_rank": 408, "title": "Germany's Merck seeks drug development partners", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T19:37:00.000+02:00", "replies_count": 0, "uuid": "41afb881b0eccec101af2c71f51a8ffdb806e27a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-merck-results-partnerships/germanys-merck-seeks-drug-development-partners-idUSKCN1GK1H0", "ord_in_thread": 0, "title": "Germany's Merck seeks drug development partners", "locations": [], "entities": {"persons": [{"name": "stefan oschmann", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}], "locations": [{"name": "germany", "sentiment": "none"}, {"name": "darmstadt", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "merck kgaa", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "nesn", "sentiment": "none"}, {"name": "nestle", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DARMSTADT, Germany (Reuters) - German drugs and chemicals group Merck KGaA ( MRCG.DE ) is open to sharing development costs for its mid-stage pharmaceuticals pipeline with external partners, it said on Thursday after flagging a decline in earnings this year.\n“We are very open to partnerships ... we are in talks with many players,” Chief Executive Stefan Oschmann told a news conference after the release of fourth-quarter results, pointing in particular to evobrutinib, a so-called BTK inhibitor that suppresses autoimmune diseases such as rheumatoid arthritis.\n“We have a full, very good pipeline and we have to see how we can finance the development of this pipeline so that it is not a burden on our financial results.”\nMerck earlier flagged a fall in operating profit this year, citing Chinese competition in liquid crystals used in flat screens and higher drug development expenses, prompting a more than 5 percent drop in its share price.\nThe planned sale of its consumer healthcare unit, with proceeds earmarked to fund development work, has hit a snag after sources said that Nestle ( NESN.S ) dropped out of the bidding and prices proposed by remaining suitors fell short of Merck’s expectations.\nOther experimental drugs from Merck’s labs that analysts have described as promising include an immuno-oncology drug known as bifunctional fusion protein as well as oral cancer drug tepotinib.\nReporting by Ludwig Burger; Editing by David Goodman\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T19:37:00.000+02:00", "crawled": "2018-03-09T14:36:44.057+02:00", "highlightTitle": ""}